MX2018010484A - Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. - Google Patents
Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.Info
- Publication number
- MX2018010484A MX2018010484A MX2018010484A MX2018010484A MX2018010484A MX 2018010484 A MX2018010484 A MX 2018010484A MX 2018010484 A MX2018010484 A MX 2018010484A MX 2018010484 A MX2018010484 A MX 2018010484A MX 2018010484 A MX2018010484 A MX 2018010484A
- Authority
- MX
- Mexico
- Prior art keywords
- cpf1
- crispr
- compositions
- components
- related methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 238000010443 CRISPR/Cpf1 gene editing Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Composiciones y métodos relacionados con CRISPR/Cpf1 para el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662304057P | 2016-03-04 | 2016-03-04 | |
PCT/US2017/020598 WO2017152015A1 (en) | 2016-03-04 | 2017-03-03 | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018010484A true MX2018010484A (es) | 2019-01-10 |
Family
ID=58358928
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018010484A MX2018010484A (es) | 2016-03-04 | 2017-03-03 | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. |
MX2023007841A MX2023007841A (es) | 2016-03-04 | 2018-08-30 | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007841A MX2023007841A (es) | 2016-03-04 | 2018-08-30 | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190062735A1 (es) |
EP (1) | EP3423580A1 (es) |
JP (2) | JP7251980B2 (es) |
KR (3) | KR102438360B1 (es) |
CN (1) | CN109312340A (es) |
AU (2) | AU2017226172B9 (es) |
CA (1) | CA3016331A1 (es) |
IL (2) | IL291971A (es) |
MX (2) | MX2018010484A (es) |
SG (1) | SG11201807538PA (es) |
WO (1) | WO2017152015A1 (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
EP4269577A3 (en) | 2015-10-23 | 2024-01-17 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
IL264439B1 (en) * | 2016-08-17 | 2024-04-01 | Factor Bioscience Inc | A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
CN110914426A (zh) | 2017-03-23 | 2020-03-24 | 哈佛大学的校长及成员们 | 包含核酸可编程dna结合蛋白的核碱基编辑器 |
JP2020517247A (ja) | 2017-04-18 | 2020-06-18 | イエール ユニバーシティ | Tリンパ球ゲノム操作のためのプラットフォームおよびそのインビボハイスループットスクリーニング法 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
TW201920661A (zh) * | 2017-09-18 | 2019-06-01 | 大陸商博雅輯因(北京)生物科技有限公司 | 一種基因編輯t細胞及其用途 |
JP2021500036A (ja) | 2017-10-16 | 2021-01-07 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | アデノシン塩基編集因子の使用 |
JP2021502077A (ja) * | 2017-11-06 | 2021-01-28 | エディタス・メディシン,インコーポレイテッド | 免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素 |
JP2021503284A (ja) * | 2017-11-16 | 2021-02-12 | モガム・インスティテュート・フォー・バイオメディカル・リサーチMogam Institute For Biomedical Research | 形質転換ヒト細胞およびその使用 |
AU2018383712A1 (en) * | 2017-12-11 | 2020-07-02 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
CN111788307A (zh) * | 2018-03-12 | 2020-10-16 | 南京北恒生物科技有限公司 | 工程化的嵌合向导rna及其用途 |
AU2019255323A1 (en) * | 2018-04-18 | 2020-10-29 | Yale University | Compositions and methods for multiplexed tumor vaccination with endogenous gene activation |
WO2020068196A2 (en) * | 2018-06-18 | 2020-04-02 | The Regents Of The University Of California | Proteins that inhibit cas12a (cpf1), a crispr-cas nuclease |
US20210322473A1 (en) * | 2018-07-18 | 2021-10-21 | The General Hospital Corporation | Modified t cells and methods of their use |
US20220016166A1 (en) * | 2018-09-21 | 2022-01-20 | Cafa Therapeutics Limited | T-cell expressing chimeric receptor |
AU2019362879A1 (en) * | 2018-10-16 | 2021-05-27 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
KR20210111276A (ko) * | 2019-01-04 | 2021-09-10 | 스텔레이트 바이오세러퓨틱스 인코포레이티드 | 원형 단일 가닥 dna를 이용한 목표 게놈 변형 |
KR20210129105A (ko) | 2019-02-15 | 2021-10-27 | 에디타스 메디신, 인코포레이티드 | 면역치료법을 위한 변형된 자연 살해(nk) 세포 |
BR112021018607A2 (pt) | 2019-03-19 | 2021-11-23 | Massachusetts Inst Technology | Métodos e composições para editar sequências de nucleotídeos |
CA3140393A1 (en) * | 2019-06-04 | 2020-12-10 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
US20200407776A1 (en) * | 2019-06-26 | 2020-12-31 | Integrated Dna Technologies, Inc. | Compositions and methods for improved detection of genomic editing events |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
AU2020324386A1 (en) * | 2019-08-02 | 2022-02-24 | Monsanto Technology Llc | Methods and compositions to promote targeted genome modifications using HUH endonucleases |
WO2021050565A1 (en) * | 2019-09-09 | 2021-03-18 | Oregon Health & Science University | Crispr-mediated capture of nucleic acids |
CN110904239B (zh) * | 2019-12-25 | 2020-11-10 | 武汉博杰生物医学科技有限公司 | 肺癌相关分子标志物基因突变的检测试剂盒与检测方法 |
AU2021216418A1 (en) * | 2020-02-05 | 2022-09-01 | Danmarks Tekniske Universitet | Compositions and methods for targeting, editing or modifying human genes |
CN116096873A (zh) | 2020-05-08 | 2023-05-09 | 布罗德研究所股份有限公司 | 同时编辑靶标双链核苷酸序列的两条链的方法和组合物 |
WO2021236987A2 (en) * | 2020-05-20 | 2021-11-25 | The Administrators Of The Tulane Educational Fund | Crispr-based assay for detecting pathogens in samples |
EP4165171A1 (en) | 2020-06-12 | 2023-04-19 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
JP2023548588A (ja) * | 2020-10-30 | 2023-11-17 | アーバー バイオテクノロジーズ, インコーポレイテッド | Tracを標的とするrnaガイドを含む組成物及びその使用 |
AU2021369840A1 (en) * | 2020-10-30 | 2023-06-01 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting b2m and uses thereof |
CN116334037A (zh) * | 2020-11-11 | 2023-06-27 | 山东舜丰生物科技有限公司 | 新型Cas酶和系统以及应用 |
EP4251741A1 (en) | 2020-11-30 | 2023-10-04 | CRISPR Therapeutics AG | Gene-edited natural killer cells |
JP2023552998A (ja) * | 2020-12-03 | 2023-12-20 | ンカルタ・インコーポレイテッド | 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
EP4263820A1 (en) * | 2020-12-17 | 2023-10-25 | Monsanto Technology LLC | Engineered ssdnase-free crispr endonucleases |
AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
KR102428773B1 (ko) * | 2021-04-21 | 2022-08-05 | (주)지플러스생명과학 | 분리형 crRNA 및 이를 이용한 CRISPR-Cas 시스템 |
KR20240051112A (ko) | 2021-07-01 | 2024-04-19 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 관련 방법 |
AU2022335499A1 (en) * | 2021-08-27 | 2024-02-22 | Metagenomi, Inc. | Enzymes with ruvc domains |
JP2023107748A (ja) * | 2022-01-24 | 2023-08-03 | 美洛生物科技股▲ふん▼有限公司 | 合成rna断片及びrna依存性増幅のためのその使用 |
WO2023164625A2 (en) * | 2022-02-25 | 2023-08-31 | Georgia Tech Research Corporation | Modified plant virus system for delivery of nucleic acids into mammalian cells |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3309248T3 (da) | 2013-05-29 | 2021-08-02 | Cellectis | Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system |
CN106103475B (zh) | 2014-03-11 | 2021-01-12 | 塞勒克提斯公司 | 产生同种异体移植相容的t细胞的方法 |
AU2015247323B2 (en) * | 2014-04-18 | 2021-07-01 | Editas Medicine, Inc. | CRISPR-Cas-related methods, compositions and components for cancer immunotherapy |
EP3215623A4 (en) * | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
IL254734B2 (en) * | 2015-03-27 | 2023-09-01 | Harvard College | Modified t cells and methods for their preparation and use |
US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
-
2017
- 2017-03-03 CN CN201780027036.0A patent/CN109312340A/zh active Pending
- 2017-03-03 KR KR1020187028616A patent/KR102438360B1/ko active IP Right Grant
- 2017-03-03 KR KR1020237033935A patent/KR20230146127A/ko not_active Application Discontinuation
- 2017-03-03 WO PCT/US2017/020598 patent/WO2017152015A1/en active Application Filing
- 2017-03-03 SG SG11201807538PA patent/SG11201807538PA/en unknown
- 2017-03-03 MX MX2018010484A patent/MX2018010484A/es unknown
- 2017-03-03 JP JP2018546483A patent/JP7251980B2/ja active Active
- 2017-03-03 IL IL291971A patent/IL291971A/en unknown
- 2017-03-03 EP EP17711928.6A patent/EP3423580A1/en active Pending
- 2017-03-03 KR KR1020227029563A patent/KR102587132B1/ko active IP Right Grant
- 2017-03-03 AU AU2017226172A patent/AU2017226172B9/en active Active
- 2017-03-03 CA CA3016331A patent/CA3016331A1/en active Pending
-
2018
- 2018-08-15 IL IL261163A patent/IL261163B2/en unknown
- 2018-08-30 MX MX2023007841A patent/MX2023007841A/es unknown
- 2018-09-04 US US16/121,152 patent/US20190062735A1/en active Pending
-
2023
- 2023-03-23 JP JP2023046534A patent/JP2023089005A/ja active Pending
- 2023-11-15 AU AU2023266284A patent/AU2023266284A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190062735A1 (en) | 2019-02-28 |
AU2017226172A1 (en) | 2018-09-27 |
IL291971A (en) | 2022-06-01 |
KR20230146127A (ko) | 2023-10-18 |
JP2023089005A (ja) | 2023-06-27 |
KR102438360B1 (ko) | 2022-08-31 |
JP7251980B2 (ja) | 2023-04-04 |
SG11201807538PA (en) | 2018-09-27 |
KR102587132B1 (ko) | 2023-10-11 |
IL261163A (en) | 2018-10-31 |
AU2023266284A1 (en) | 2023-12-07 |
CN109312340A (zh) | 2019-02-05 |
IL261163B (en) | 2022-10-01 |
AU2017226172B9 (en) | 2023-08-24 |
JP2019507599A (ja) | 2019-03-22 |
AU2017226172A2 (en) | 2018-10-04 |
MX2023007841A (es) | 2023-07-07 |
AU2017226172B2 (en) | 2023-08-17 |
WO2017152015A1 (en) | 2017-09-08 |
CA3016331A1 (en) | 2017-09-08 |
KR20180118204A (ko) | 2018-10-30 |
EP3423580A1 (en) | 2019-01-09 |
IL261163B2 (en) | 2023-02-01 |
KR20220124278A (ko) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
EP3800248A3 (en) | Crispr-cas-related methods, compositions and components for cancer immunotherapy | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
MX2018011114A (es) | Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías. | |
MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
TW201613648A (en) | Compounds and compositions for immunotherapy | |
IL253979A0 (en) | Methods, preparations and kits for cancer treatment | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX370807B (es) | Anticuerpos que se unen a axl. | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
EP3703711A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ANTI-ROR1 IMMUNOTHERAPY | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
MX2020006297A (es) | Variantes de cd19. | |
EP3413906A4 (en) | COMBINATION COMPOSITIONS FOR CANCER TREATMENT, METHOD AND USES | |
EP3688023A4 (en) | PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT |